News
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...
SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback